Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban

Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):346-8. doi: 10.1002/pds.3916.

Authors

Maja Hellfritzsch¹, Per Damkier^{1

2}, Anton Pottegård¹, Thor Grønlykke³, Erik L Grove⁴

Affiliations

¹ Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense C, Denmark.
² Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense C, Denmark.
³ Institute of Rational Pharmacotherapy, Danish Health and Medicines Authority, Copenhagen S, Denmark.
⁴ Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.

PMID: 26932584
DOI: 10.1002/pds.3916

No abstract available

Publication types

Letter

MeSH terms

Anticoagulants* / adverse effects
Anticoagulants* / urine
Clinical Trials as Topic* / statistics & numerical data
Hemorrhage / chemically induced
Hemorrhage / epidemiology
Hemorrhage / metabolism
Humans
Kidney / metabolism*
Kidney Diseases / urine
Kidney Function Tests
Metabolic Clearance Rate
Pyrazoles* / adverse effects
Pyrazoles* / urine
Pyridones* / adverse effects
Pyridones* / urine

Substances

Anticoagulants
Pyrazoles
Pyridones
apixaban